Intravenous (IV) Ibuprofen Market is Generating Revenue of $14.2 Billion by 2022 | CSL Limited, Sandor Medicaids Pvt. Ltd.

The pain indication segment accounted for over three-fourths share in 2015 and is expected to maintain its dominance throughout the forecast period.

Download Detailed COVID-19 Impact Sample Report at @ https://www.alliedmarketresearch.com/request-for-customization/1387?reqfor=covid

The global intravenous (IV) ibuprofen market is projected to reach $14.2 million by 2022.

COVID-19 scenario-

1) Due to the global pandemic all over the world, the medical devices manufacturers are majorly focusing on essential medical devices production including ventilators and diagnostics.

2) However, due to the precautionary measures taken by governments in various regions, the supply chain has been hampered. Which may result in shortage of devices in certain locations.

3) Food and Drugs Administration (FDA), on the other hand, shared a COVID-19 guidance with medical device manufacturers to notify the agency about changes that could affect availability of their products.

The major factors that boost the market growth include, increase in adoption of intravenous mode of drug delivery for acute pain management due to faster onset of action as compared to the other routes (oral and transdermal mode of administration) and targeted drug delivery property.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/1387

The market growth is further augmented as IV ibuprofen improves pain management with less dependence on opioid analgesic medication, which may lead to several health complications such as sedation, dizziness, and others. Caldolor (Cumberland Pharmaceuticals) is the only injectable ibuprofen drug available in the market; hence, it has huge demand with minimal competition. However, numerous factors are likely to restrain the market growth such as lengthy approval process and limited geographic (country specific) approvals. The IV Ibuprofen market is estimated to grow at a CAGR of 20.0% during 2016 and 2022.

Adults end user segment accounted for major share in 2015, and is projected to maintain this trend throughout the forecast period. This is because the IV Ibuprofen was not prescribed for pediatrics until 2014. Pediatrics is projected to be the fastest growing end user segment, owing to the growing need for rapid pain and fever management in children (to avoid damage caused by inflammation and high body temperature) and increasing awareness about the use of IV Ibuprofen in children.

To know more about the report, visit the website at @ https://www.alliedmarketresearch.com/Intravenous-Ibuprofen-market

The U.S. is anticipated to remain the highest revenue-generating region during the forecast period, owing to the widespread adoption of IV Ibuprofen for treating pain and fever. However, Australia is expected to grow rapidly during the forecast period, owing to recent entry of IV Ibuprofen in this market, increasing awareness of non-steroidal anti-inflammatory drugs, and shifting trend towards intravenous mode of drug delivery.

The Major Key Players Are:

• Cumberland Pharmaceuticals Inc.
• Alveda Pharmaceuticals, Inc.
• (Acquired by Teligent, Inc.)
• CSL Limited
• Sandor Medicaids Pvt. Ltd.
• PT. Soho Industri Pharmasi
• Germin MED
• Grifols S.A.
• Harbin Gloria Pharmaceuticals Co., Ltd.
• Al Nabeel International Ltd.
• Laboratorios Valmorca, C.A.

Similar Reports:

Fertility Services Market : https://www.einnews.com/pr_news/527711812/fertility-services-market-to-see-record-break-revenue-27-15-billion-by-2026

Brain Health Supplements Market : https://www.einnews.com/pr_news/527715928/brain-health-supplements-market-to-reach-valuation-of-5-81-billion-by-2023

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.